Transforming growth factor-beta (TGF-β) and brain tumours

Journal of Clinical Neuroscience

Volumn 15, Issue 8, 2008, Pages 845-855

  Luwor, Rodney B ^a   Kaye, Andrew H ^a   Zhu, Hong Jian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Glioma; Signalling; TGF ; Therapy

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MUELLERIAN INHIBITING FACTOR; MYOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; RAC1 PROTEIN; SCATTER FACTOR; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNINDEXED DRUG; WNT3 PROTEIN;

BRAIN TUMOR; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; BRAIN NEOPLASMS; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 45849110280     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.01.003     Document Type: Review

References (105)

1. Leon S.P., Zhu J., and Black P.M. Genetic aberrations in human brain tumors. Neurosurgery 34 (1994) 708-722
2. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
3. Massague J. TGF-beta signal transduction. Ann Rev Biochem 67 (1998) 753-791
4. Heldin C.H., Miyazono K., and ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390 (1997) 465-471
5. Tsukazaki T., Chiang T.A., Davison A.F., et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95 (1998) 779-791
6. Xu L., Chen Y.G., and Massague J. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol 2 (2000) 559-562
7. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
8. Massague J., and Gomis R.R. The logic of TGFbeta signaling. FEBS Lett 580 (2006) 2811-2820
9. Moustakas A., and Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 118 (2005) 3573-3584
10. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
11. Dziembowska M., Danilkiewicz M., Wesolowska A., et al. Cross-talk between Smad and p38 MAPK signalling in transforming growth factor beta signal transduction in human glioblastoma cells. Biochem Biophys Res Commun 354 (2007) 1101-1106
12. Grady W.M. Transforming growth factor-beta, Smads, and cancer. Clin Cancer Res 11 (2005) 3151-3154
13. Kang Y. Pro-metastasis function of TGFbeta mediated by the Smad pathway. J Cell Biochem 98 (2006) 1380-1390
14. Bhowmick N.A., Ghiassi M., Bakin A., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12 (2001) 27-36
15. Afrakhte M., Moren A., Jossan S., et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 249 (1998) 505-511
16. Bitzer M., von Gersdorff G., Liang D., et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 14 (2000) 187-197
17. Jenkins B.J., Grail D., Nheu T., et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11 (2005) 845-852
18. Labbe E., Letamendia A., and Attisano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci USA 97 (2000) 8358-8363
19. Song K., Wang H., Krebs T.L., et al. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. Embo J 25 (2006) 58-69
20. Ulloa L., Doody J., and Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397 (1999) 710-713
21. Chen Y.G., Liu F., and Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. Embo J 16 (1997) 3866-3876
22. Onichtchouk D., Chen Y.G., Dosch R., et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401 (1999) 480-485
23. Nakao A., Afrakhte M., Moren A., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389 (1997) 631-635
24. Zhu H.J., Iaria J., and Sizeland A.M. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem 274 (1999) 32258-32264
25. Kavsak P., Rasmussen R.K., Causing C.G., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6 (2000) 1365-1375
26. Murakami G., Watabe T., Takaoka K., et al. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14 (2003) 2809-2817
27. Denissova N.G., and Liu F. Repression of endogenous Smad7 by Ski. J Biol Chem 279 (2004) 28143-28148
28. Golestaneh N., and Mishra B. TGF-beta, neuronal stem cells and glioblastoma. Oncogene 24 (2005) 5722-5730
29. Iavarone A., and Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 387 (1997) 417-422
30. Isoe S., Naganuma H., Nakano S., et al. Resistance to growth inhibition by transforming growth factor-beta in malignant glioma cells with functional receptors. J Neurosurg 88 (1998) 529-534
31. Rich J.N., Zhang M., Datto M.B., et al. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274 (1999) 35053-35058
32. Seoane J., Le H.V., Shen L., et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 (2004) 211-223
33. Pan J.J., Chang W.J., Barone T.A., et al. Increased expression of TGF-beta1 reduces tumor growth of human U-87 glioblastoma cells in vivo. Cancer Immunol Immunother 55 (2006) 918-927
34. Ashley D.M., Kong F.M., Bigner D.D., et al. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 58 (1998) 302-309
35. Hallahan A.R., Pritchard J.I., Chandraratna R.A., et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9 (2003) 1033-1038
36. Piccirillo S.G., Reynolds B.A., Zanetti N., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444 (2006) 761-765
37. Dowdy S.C., Mariani A., Reinholz M.M., et al. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol 96 (2005) 368-373
38. Kleeff J., Ishiwata T., Maruyama H., et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18 (1999) 5363-5372
39. Korchynskyi O., Landstrom M., Stoika R., et al. Expression of Smad proteins in human colorectal cancer. Int J Cancer 82 (1999) 197-202
40. Fukuchi M., Nakajima M., Fukai Y., et al. Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer 108 (2004) 818-824
41. Reed J.A., Bales E., Xu W., et al. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 61 (2001) 8074-8078
42. Zhang F., Lundin M., Ristimaki A., et al. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63 (2003) 5005-5010
43. Kong X.T., Choi S.H., Inoue A., et al. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res 57 (1997) 3772-3778
44. Izumoto S., Arita N., Ohnishi T., et al. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett 112 (1997) 251-256
45. Kjellman C., Olofsson S.P., Hansson O., et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89 (2000) 251-258
46. Yamada N., Kato M., Yamashita H., et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62 (1995) 386-392
47. Jachimczak P., Hessdorfer B., Fabel-Schulte K., et al. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65 (1996) 332-337
48. Bodmer S., Strommer K., Frei K., et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143 (1989) 3222-3229
49. Horst H.A., Scheithauer B.W., Kelly P.J., et al. Distribution of transforming growth factor-beta 1 in human astrocytomas. Hum Pathol 23 (1992) 1284-1288
50. Schneider T., Sailer M., Ansorge S., et al. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 79 (2006) 61-65
51. Zhang L., Sato E., Amagasaki K., et al. Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg 105 (2006) 119-128
52. Bruna A., Darken R.S., Rojo F., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11 (2007) 147-160
53. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
54. Guo P., Hu B., Gu W., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162 (2003) 1083-1093
55. Helseth E., Dalen A., Unsgaard G., et al. Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line. J Neurooncol 6 (1988) 277-283
56. Held-Feindt J., Lutjohann B., Ungefroren H., et al. Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells. J Neurooncol 63 (2003) 117-127
57. Hunter K.E., Sporn M.B., and Davies A.M. Transforming growth factor-betas inhibit mitogen-stimulated proliferation of astrocytes. Glia 7 (1993) 203-211
58. Vergeli M., Mazzanti B., Ballerini C., et al. Transforming growth factor-beta 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J Neurosci Res 40 (1995) 127-133
59. Maher E.A., Furnari F.B., Bachoo R.M., et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 15 (2001) 1311-1333
60. Platten M., Wick W., Wild-Bode C., et al. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 268 (2000) 607-611
61. D'Abaco G.M., and Kaye A.H. Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14 (2007) 1041-1048
62. Merzak A., McCrea S., Koocheckpour S., et al. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 70 (1994) 199-203
63. Paulus W., Baur I., Huettner C., et al. Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp Neurol 54 (1995) 236-244
64. Weiler M., Bahr O., Hohlweg U., et al. BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death Differ 13 (2006) 1156-1169
65. Han X., Stewart Jr. J.E., Bellis S.L., et al. TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate. Oncogene 20 (2001) 7976-7986
66. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 6 (1990) 597-641
67. Platten M., Wick W., and Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52 (2001) 401-410
68. Uhl M., Aulwurm S., Wischhusen J., et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64 (2004) 7954-7961
69. Wick W., Platten M., and Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53 (2001) 177-185
70. Izumoto S., Ohnishi T., Arita N., et al. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res 56 (1996) 1440-1444
71. Montgomery A.M., Becker J.C., Siu C.H., et al. Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol 132 (1996) 475-485
72. Stewart H.J., Rougon G., Dong Z., et al. TGF-betas upregulate NCAM and L1 expression in cultured Schwann cells, suppress cyclic AMP-induced expression of O4 and galactocerebroside, and are widely expressed in cells of the Schwann cell lineage in vivo. Glia 15 (1995) 419-436
73. Tsuzuki T., Izumoto S., Ohnishi T., et al. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. J Clin Pathol 51 (1998) 13-17
74. Wick W., Grimmel C., Wild-Bode C., et al. Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 21 (2001) 3360-3368
75. Wick W., Wild-Bode C., Frank B., et al. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 91 (2004) 1275-1283
76. Wild-Bode C., Weller M., and Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg 94 (2001) 978-984
77. Wick W., Wagner S., Kerkau S., et al. BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett 440 (1998) 419-424
78. Rooprai H.K., Rucklidge G.J., Panou C., et al. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 82 (2000) 52-55
79. Friese M.A., Wischhusen J., Wick W., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64 (2004) 7596-7603
80. Nakano A., Tani E., Miyazaki K., et al. Expressions of matrilysin and stromelysin in human glioma cells. Biochem Biophys Res Commun 192 (1993) 999-1003
81. Nakagawa T., Kubota T., Kabuto M., et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81 (1994) 69-77
82. Rao J.S., Steck P.A., Mohanam S., et al. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 53 (1993) 2208-2211
83. Li M.O., Wan Y.Y., Sanjabi S., et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24 (2006) 99-146
84. Zuber P., Kuppner M.C., and De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18 (1988) 1623-1626
85. Rook A.H., Kehrl J.H., Wakefield L.M., et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136 (1986) 3916-3920
86. Weller M., and Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21 (1995) 128-151
87. Gamble J.R., and Vadas M.A. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta 1. J Immunol 146 (1991) 1149-1154
88. Eisele G., Wischhusen J., Mittelbronn M., et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129 (2006) 2416-2425
89. Friese M.A., Platten M., Lutz S.Z., et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 63 (2003) 8996-9006
90. Hayakawa Y., Kelly J.M., Westwood J.A., et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169 (2002) 5377-5381
91. Bertone S., Schiavetti F., Bellomo R., et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 29 (1999) 23-29
92. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (2001) 506-513
93. Wong M.L., Kaye A.H., and Hovens C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14 (2007) 301-308
94. Burghardt I., Tritschler F., Opitz C.A., et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun 354 (2007) 542-547
95. Hjelmeland M.D., Hjelmeland A.B., Sathornsumetee S., et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3 (2004) 737-745
96. Schlingensiepen K.H., Schlingensiepen R., Steinbrecher A., et al. Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17 (2006) 129-139
97. Fakhrai H., Dorigo O., Shawler D.L., et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93 (1996) 2909-2914
98. Stander M., Naumann U., Dumitrescu L., et al. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 5 (1998) 1187-1194
99. Leitlein J., Aulwurm S., Waltereit R., et al. Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 166 (2001) 7238-7243
100. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3 (2004) 1011-1022
101. Fakhrai H., Mantil J.C., Liu L., et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 13 (2006) 1052-1060
102. Mercapide J., Lopez De Cicco R., Bassi D.E., et al. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 8 (2002) 1740-1746
103. Platten M., Wild-Bode C., Wick W., et al. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93 (2001) 53-61
104. Bierie B., and Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6 (2006) 506-520
105. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100 (2003) 8621-8623